MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million

Dow Jones10-26

By Connor Hart

MEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics that sent its stock 30% higher, to $3.55, in after-hours trading.

Shares, which ended Friday's regular session flat at $2.73, are down 53% since the beginning of the year.

The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. The agreement includes relevant intellectual property rights, technology and contracts, MEI said in a regulatory filing.

Under the terms of the agreement, Aardvark made an initial $500,000 cash payment. The company may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 25, 2024 17:54 ET (21:54 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478196067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-26 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478196067","market":"nz","top_or_hot":-1,"title":"MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> inked a deal valued at up to $62 million with Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> that sent its stock 30% higher, to $3.55, in after-hours trading. \n</p>\n<p>\n  Shares, which ended Friday's regular session flat at $2.73, are down 53% since the beginning of the year. \n</p>\n<p>\n  The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. The agreement includes relevant intellectual property rights, technology and contracts, MEI said in a regulatory filing. \n</p>\n<p>\n  Under the terms of the agreement, Aardvark made an initial $500,000 cash payment. The company may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 25, 2024 17:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 05:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\nMEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics that sent its stock 30% higher, to $3.55, in after-hours trading. \n\n\n  Shares, which ended Friday's...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478196067","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478196067","pubTimestamp":1729893240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics that sent its stock 30% higher, to $3.55, in after-hours trading.Shares, which ended Friday's regular session flat at $2.73, are down 53% since the beginning of the year.The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. The agreement includes relevant intellectual property rights, technology and contracts, MEI said in a regulatory filing.Under the terms of the agreement, Aardvark made an initial $500,000 cash payment. The company may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEI":"Methode Electronics Inc","BK4145":"电子制造服务","MEIP":"MEI Pharma"},"translate_title":"签订价值高达6200万美元的资产购买协议后MEI股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEI":1,"MEIP":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nMEI Pharma inked a deal valued at up to $62 million with Aardvark Therapeutics that sent its stock 30% higher, to $3.55, in after-hours trading. \n\n\n  Shares, which ended Friday's regular session flat at $2.73, are down 53% since the beginning of the year. \n\n\n  The pharmaceutical companies entered an asset purchase agreement in which MEI sold its rights, title and interest in and to certain assets related to the company's novel drug candidate for the treatment of solid tumors, dubbed ME-344. The agreement includes relevant intellectual property rights, technology and contracts, MEI said in a regulatory filing. \n\n\n  Under the terms of the agreement, Aardvark made an initial $500,000 cash payment. The company may make payments up to $62 million, payable upon the achievement of certain milestones regulatory approval and sales. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 17:54 ET (21:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478196067"}